Indications for use: Treatment of infections, the causative agents of which are sensitive to the components of the drug:
- respiratory tract infections, especially pneumonia, as well as infections of the ENT organs;
- infections of the abdominal organs (peritonitis, infections of the biliary tract and gastrointestinal tract);
- urinary tract infections;
- genital infections, including gonorrhea;
- sepsis;
- infections of bones, joints, soft tissues, skin, as well as wound infections;
- infections in patients with weakened immune protection;
meningitis;
disseminated Lyme borreliosis (early and late stages of the disease).
Preoperative prevention of infections during surgical interventions on organs of the gastrointestinal tract, biliary tract, urinary tract and during gynecological procedures, but only in cases of potential or known contamination.

When prescribing Euroceftase, it is necessary to adhere to official recommendations on antibiotic therapy, in particular, recommendations on the prevention of antibiotic resistance.

Contraindication: Hypersensitivity to ceftriaxone or any other cephalosporin. History of severe hypersensitivity reactions (eg, anaphylactic reactions) to any other type of beta-lactam antibacterial agents (penicillins, monobactams, and carbapenems).

Ceftriaxone is contraindicated:

premature newborns aged ≤ 41 weeks, taking into account the period of intrauterine development (gestational age + age after birth)*;

for full-term newborns (age ≤ 28 days):

with hyperbilirubinemia, jaundice, hypoalbuminemia or acidosis, since in such conditions the binding of bilirubin is probably impaired*;
who require (or are expected to require) intravenous administration of calcium preparations or infusions of calcium-containing solutions, as there is a risk of the formation of precipitates of the calcium salt of ceftriaxone (see the sections "Particulars of use" and "Adverse reactions").
* In vitro studies have shown that ceftriaxone can displace bilirubin from binding to serum albumin, leading to a possible risk of bilirubin encephalopathy in such patients.

Before intramuscular administration of ceftriaxone, it is necessary to exclude the presence of contraindications to the use of lidocaine, if it is used as a solvent (see the section "Method of administration and dosage"). See instructions for medical use of lidocaine, especially contraindications.

Ceftriaxone solutions containing lidocaine should never be administered intravenously.